@article{8d358c824902467491754df77e8a0e83,
title = "Supporting COVID-19 School Safety for Children With Disabilities and Medical Complexity",
abstract = "Children with intellectual and developmental disabilities (IDDs) and children with medical complexity (CMC) have been disproportionally impacted by the coronavirus disease 2019 pandemic, including school closures. Children with IDDs and CMC rely on schools for a vast array of educational, therapeutic, medical, and social needs. However, maintaining safe schools for children with IDDs and CMC during the coronavirus disease 2019 pandemic may be difficult because of the unique challenges of implementing prevention strategies, such as masking, social distancing, and hand hygiene in this high-risk environment. Furthermore, children with IDDs and CMC are at a higher risk of infectious complications and mortality, underscoring the need for effective mitigation strategies. The goal of this report is to describe the implementation of several screening testing models for severe acute respiratory syndrome coronavirus 2 in this high-risk population. By describing these models, we hope to identify generalizable and scalable approaches to facilitate safe school operations for children with IDDs and CMC during the current and future pandemics.",
author = "Sherby, {Michael R.} and Kalb, {Luther G.} and Coller, {Ryan J.} and DeMuri, {Gregory P.} and Sabrina Butteris and Foxe, {John J.} and Zand, {Martin S.} and Freedman, {Edward G.} and Stephen Dewhurst and Newland, {Jason G.} and Gurnett, {Christina A.}",
note = "Funding Information: Funded in part by the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) (U24 MD016258; National Institutes of Health [NIH] Agreement No.'s 1 OT2 HD107543-01, 1 OT2 HD107544-01, 1 OT2 HD107553-01, 1 OT2 HD107555-01, 1 OT2 HD107556-01, 1 OT2 HD107557-01, 1 OT2 HD107558-01, 1 OT2 HD107559-01); the Trial Innovation Network, which is an innovative collaboration addressing critical roadblocks in clinical research and accelerating the translation of novel interventions into life-saving therapies; and the National Institute of Child Health and Human Development contract (HHSN275201000003I) for the Pediatric Trials Network (principal investigator, Daniel Benjamin). Dr Coller reports funding from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NLHBI) (1R34HL153570-01A1), the Health Resources and Services Administration of the Department of Health and Human Services (DHHS) (UA6MC31101), and a Clinical and Translational Science Award from the NIH National Center for Advancing Translational Sciences (NCATS) (UL1TR000427). Dr Freedman reports funding from the DHHS, US Public Health Service, and NIH (P50HD103536 and U01DA050988). Dr Foxe reports funding from the DHHS, US Public Health Service, and NIH (P50 HD103536 and U01DA050988). Dr Zand reports funding from the NIH NCATS (UL1 TR002001). Dr Dewhurst reports funding from the NIH. Dr Newland reports funding from the Agency for Healthcare Research and Quality, NIH, and a research grant from Merck. Dr Gurnett reports funding from the NIH NCATS (UL1TR002345), the Eunice Kennedy Shriver Institute of Child Health and Human Development (R03HD104065; P50HD103525), and the NIH National Institute of Arthritis and Musculoskeletal and Skin Funding Information: FUNDING: Funded in part by the Rapid Acceleration of Diagnostics Underserved Populations (RADx-UP) (U24 MD016258; National Institutes of Health [NIH] Agreement No.{\textquoteright}s 1 OT2 HD107543-01, 1 OT2 HD107544-01, 1 OT2 HD107553-01, 1 OT2 HD107555-01, 1 OT2 HD107556-01, 1 OT2 HD107557-01, 1 OT2 HD107558-01, 1 OT2 HD107559-01); the Trial Innovation Network, which is an innovative collaboration addressing critical roadblocks in clinical research and accelerating the translation of novel interventions into life-saving therapies; and the National Institute of Child Health and Human Development contract (HHSN275201000003I) for the Pediatric Trials Network (principal investigator, Daniel Benjamin). Dr Coller reports funding from the National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NLHBI) (1R34HL153570-01A1), the Health Resources and Services Administration of the Department of Health and Human Services (DHHS) (UA6MC31101), and a Clinical and Translational Science Award from the NIH National Center for Advancing Translational Sciences (NCATS) (UL1TR000427). Dr Freedman reports funding from the DHHS, US Public Health Service, and NIH (P50HD103536 and U01DA050988). Dr Foxe reports funding from the DHHS, US Public Health Service, and NIH (P50 HD103536 and U01DA050988). Dr Zand reports funding from the NIH NCATS (UL1 TR002001). Dr Dewhurst reports funding from the NIH. Dr Newland reports funding from the Agency for Healthcare Research and Quality, NIH, and a research grant from Merck. Dr Gurnett reports funding from the NIH NCATS (UL1TR002345), the Eunice Kennedy Shriver Institute of Child Health and Human Development (R03HD104065; P50HD103525), and the NIH National Institute of Arthritis and Musculoskeletal and Skin Publisher Copyright: Copyright {\textcopyright} 2022 by the American Academy of Pediatrics",
year = "2022",
month = feb,
day = "1",
doi = "10.1542/PEDS.2021-054268H",
language = "English (US)",
volume = "149",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
}